Business
Therma Bright to Begin AcuVid(TM) U.S. Clinical Performance Study with Receipt of IRB Conditional Approval
Toronto, Ontario--(Newsfile Corp. - November 12, 2021) - Therma Bright Inc. (TSXV: THRM) (OT...
About this update from Therma Bright Inc.
[{"type":"text","content":"Therma Bright to Begin AcuVid(TM) U.S. Clinical Performance Study with Receipt of IRB Conditional ApprovalToronto, Ontario--(Newsfile Corp. - November 12, 2021) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (\"Therma\" or the \"Company\"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to announce that it will begin its U.S. clinical performance study with the receipt of Institutional Review Board's (IRB) conditional approval late yesterday, Thursday, November 11, 2021. The clinical performance study, per U.S. Food & Drug Administration guidance, will being immediately at three (3) U.S.-based clinics. The results will complement the Brazilian clinical study and other requested test data that have been submitted to the FDA over the past four (4) months, beginning in July 2021.\"We're pleased to have received IRB conditional approval for our U.S. clinical performance study,\" shared Rob Fia, CEO of Therma Bright. \"Therma Bright can begin moving forward in our efforts with three (3) pre-selected U.S. clinics. Based on current COVID-19 infection rates, we expect the study results to be delivered to the FDA within the next few weeks, as part of our AcuVid™ application for Emergency Use Authorization (EUA).\"Since mid-July 2021, the Company has actively engaged with FDA executives, doctors and scientists on it AcuVid™ COVID-19 Rapid Antigen Saliva Test application, and anticipates Emergency Use Authorization (EUA) following final FDA review.Therma Bright is not making any express or implied claims that its test product has the ability to eliminate or cure COVID-19 or the SARS-CoV-2 virus.About Therma Bright Inc.: Therma Bright, developer of the AcuVid™ COVID-19 Rapid Antigen Saliva Test, is a progressive medical diagnostic and device technology company focused on providing consumers and medical professionals with quality, innovative solutions that address some of today's most important medical and healthcare challenges. The Company's initial breakthrough proprietary technology delivers effective, non-invasive, and pain-free skincare. Therma Bright received a Class II medical device status from the FDA for its platform technology that is indicated for the relief of the pain, itch, and inflammation ...